Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin

Journal of Biomedical Materials Research - Part A

Volumn 95, Issue 1, 2010, Pages 118-128

  Lakshmi, T S Ramyaa ^a   Shanmugasundaram, N ^a,b   Shanmuganathan, S ^a,b   Karthikeyan, K ^a   Meenakshi, J ^a   Babu, Mary ^a  

^a CENTRAL LEATHER RESEARCH INSTITUTE   (India)

^b US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

Controlled release; Desulfation; Heparin; Inflammation; Microspheres

Indexed keywords

ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY AGENTS; CHITOSAN MICROSPHERES; CLOTTING CASCADE; CONTROLLED DELIVERY; CONTROLLED RELEASE; DESULFATED HEPARIN; DESULFATION; DISACCHARIDE UNITS; GLYCOSAMINOGLYCANS; HEPARIN; HETEROGENEOUS MIXTURES; IMMUNOCYTOCHEMISTRY; INFLAMMATION; OPTIMAL LOADING; PENTASACCHARIDES; PROINFLAMMATORY CYTOKINES; RELEASE KINETICS; SELECTINS; STEADY STATE CONCENTRATION; WESTERN BLOTS;

CHEMICAL MODIFICATION; MICROSPHERES; OPTIMIZATION; PATHOLOGY;

POLYSACCHARIDES;

2,3 DESULFATED HEPARIN; CHITOSAN; COLLAGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; HEPARIN DERIVATIVE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROSPHERE; MOLECULAR SCAFFOLD; UNCLASSIFIED DRUG; 2, 3 DESULFATED HEPARIN; ANTIINFLAMMATORY AGENT; AUTACOID; CALCEIN; CYTOKINE; DRUG DERIVATIVE; FLUORESCEIN DERIVATIVE; TISSUE SCAFFOLD;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CELL ASSAY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG INHIBITION; ENDOTHELIUM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKOCYTE ADHERENCE; STEADY STATE; WESTERN BLOTTING; CELL ADHESION; DRUG EFFICACY; ENDOTHELIUM CELL; LEUKOCYTE; PROTEIN EXPRESSION; BIOASSAY; CHEMISTRY; CONFORMATION; CYTOLOGY; DELAYED RELEASE FORMULATION; DRUG EFFECT; METABOLISM; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL THROMBOPLASTIN TIME; REPRODUCIBILITY; SCANNING ELECTRON MICROSCOPY;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL ASSAY; BLOOD COAGULATION; BLOTTING, WESTERN; CARBOHYDRATE CONFORMATION; CHITOSAN; COLLAGEN; CYTOKINES; DELAYED-ACTION PREPARATIONS; E-SELECTIN; ENDOTHELIAL CELLS; FLUORESCEINS; HEPARIN; HUMANS; INFLAMMATION MEDIATORS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; REPRODUCIBILITY OF RESULTS; TISSUE SCAFFOLDS;

EID: 77956473408     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32791     Document Type: Article

References (29)

1. Garga HG, Lunyin Y, Charles AH, Toshihiko T, Tasneem I, Robert JL. Sulfation patterns in heparin and heparan sulfate: Effects on the proliferation of bovine pulmonary artery smooth muscle cells. Biochem Biophys Acta 2003;1639:225-231. (Pubitemid 37421429)
2. Lever R, Hoult JRS, Clive PP. The effects of heparin and related molecules upon the adhesion of human PMNL to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-554.
3. Savu SA, Silvestro L. Adhesion "in vitro" by heparin derivatives correlates with their activity on angiogenesis in mice. J Cell Mol Med 2003;7:187-191.
4. Lawrence MB, Bainton DF, Springer TA. Neutrophil tethering to and rolling on E-selectin are separable by requirement for L-selectin. Immunity 1994;1:137-145. (Pubitemid 124000814)
5. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2007;122:743-752.
6. Wei M, Yanguang G, Meihong T, Na L, Shui H, Xianlu Z. Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. Cancer Lett 2005;229:123-126.
7. Wang JG, Mu JS, Zhu HS, Geng JG. N-desulfated non anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 2002;51:1-9.
8. Khorana AA, Abha S, Owen DA, Charles WF. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003;23:2110-2115.
9. Singh A. The use of controlled release technology in drug delivery. MURJ 2000;2:56-58.
10. Muzzarelli R, Baldassarre V, Conti F, Ferrara P, Biagini G, Gazzanelli G Vasi V. Biological activity of chitosan: Ultrastructural study. Biomaterials 1998;9:247-252.
11. Shanmugasundaram N, Ravikumar T, Babu M. Comparative physico-chemical and in vitro properties of fibrillated collagen scaffolds from different sources. J Biomater Appl 2004;18:247-264.
12. Jaseja M, Rabindra NR, Francois S, Arthur SP. Novel regio and stereo selective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence. Can J Chem 1989;67:1449.
13. Smith PK, Mallia AK, Hermanson T. Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal Biochem 1980;109:466-473.
14. Smailbegovic A, Lever R, Page CP. The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. Br J Pharmacol 2001;134:827-836.
15. Shanmuganathan S, Shanmugasundaram N, Adhirajan N, Lakshmi TSR, Babu M. Development and delivery of doxycycline from chitosan microspheres. Carbohydr Polym 2008;73:201-211.
16. Franz TJ. The finite dose technique as a valid in vitro model for the study of percutaneous absorption in man. Curr Probl Dermatol 1978;7:58-68.
17. Tsipouras N, Rix CJ, Brady PH. Solubility of silver sulfadiazine in physiological media and relevance to treatment of thermal burns with silver sulfadiazine cream. Clin Chem 1995;41:87-91.
18. Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: Structural differentiation by bi dimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2001;33:478-487.
19. Naggi A, Cristofanto B, Bisio A, Torri G, Casu B. Generation of anti-factor Xa actie, 3-O-sulfated glucosamine-rich sequenced by controlled desulfation of oversulfated heparins. Carbohydr Res 2001;336:283-290.
20. Everts M, Robert JK, Sigridur AA, Barbro NM, Tom JMM, Gerben AK, Marja JA, Van I, Dirk KFM, Gritje M. Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-Selectin directed immunoconjugate. J Immunol 2002;168:883-889.
21. Patel KD, Susan LC, Shahina W. Selectins: Critical mediators of leukocyte recruitment. Semin Immunol 2002;14:73-81.
22. Saliba MJ. Heparin in the treatment of burns: A review. Burns 2001;27:349-358.
23. Ellis RJ, Cunninggham MT, Cook JD. Laboratory heparin resistance in burn injury complicated by venous thrombosis. Burns 1999;25:749-752.
24. Ewa Kus, Andrzej B. Subcutaneous low molecular weight heparin administration promotes wound healing in rats. Pathophysiol 2006;13:81-84.
25. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9:263-268.
26. Kwon KM, Yean JC, Jung SC, Sang WK, Ji YB, Il-Jun K, Jong- GJ, Sang SL, Young HK. Blockade of cytokine induced endothelial cell adhesion molecule expression by Licorice Isoliquiritigenin through NF-kB signal disruption. Exp Biol Med 2007;32:235-245.
27. Manduteanu I, Manuela V, Felicia A, Elena D, Monica C, Luminita R, Maya S. Effect of enoxaparin on high glucose induced activation of endothelial cells. Eur J Pharmacol 2003;477:269-276. (Pubitemid 38366400)
28. Blanco MD, Gomez C, Olmo R, Muniz E, Teijon JM. Chitosan microspheres in PLG films as devices for cytarabine release. Int J Pharmacol 2000;202:29-39.
29. Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007;321:726-733. (Pubitemid 46624510)